Claudin 18.2
Claudin 18.2 as a target in gastric and oesophageal cancer.
Key point
Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression.
From: Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update (J Clin Oncol, 2026 Apr 20) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 17, 23, 19, 22, 48.
New guidelines and consensus this year
- Gastric cancer: French intergroup clinical practice guidelines for diagnosis, staging, treatment and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACHBPT, RENAPE, SNFCP)Eur J Cancer2026 Jun 3
- Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline UpdateJ Clin Oncol2026 Apr 20
- Gastric Carcinoma: Diagnosis, Staging, and TreatmentDtsch Arztebl Int2026 Jan 1
All papers from the last 12 months
289 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomesESMO Gastrointest Oncol2026 DecPMID 42787785
- Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysisESMO Gastrointest Oncol2026 DecPMID 42756942Review
- Randomized phase II trial of zolbetuximab as second-line treatment in patients with claudin 18.2-positive advanced gastric/GEJ cancer with previous zolbetuximab exposure: ZELDAESMO Gastrointest Oncol2026 DecPMID 42756594
- MET Expression in Upper Gastrointestinal Adenocarcinoma: Prevalence, Prognostic Impact, and Implications for Anti-MET Antibody-Drug Conjugate TherapyInt J Cancer2026 Nov 15PMID 42394136
- Advancing antibody drug conjugates in gastrointestinal cancersBr J Cancer2026 NovPMID 42493602Review
- CLDN18.2 targeting enhances chemotherapy sensitivity in pancreatic cancer cells and lung cancer organoidsBiochem Biophys Res Commun2026 Oct 29PMID 42772182
- Dynamic changes of claudin 18.2 expression after systemic therapy in gastric and esophagogastric junction cancerCancer2026 Oct 15PMID 42845003
- STING reprogramming by estrogen promotes neutrophil extracellular trap formation and sex-biased resistance to ADC therapyCell2026 Oct 15PMID 42838045
- Claudin 18.2: From a Tight Junction Protein to a Breakthrough Target in Solid Tumor ImmunotherapyBiomarkers2026 Oct 13PMID 42867382Review
- Importance of Inclusion of Representative Populations in Pivotal Clinical Trials: Zolbetuximab as an ExampleJ Clin Oncol2026 Oct 10PMID 42555895
More oncology trends
All specialties →Circulating tumour DNA
Liquid biopsy with ctDNA for detection, monitoring and treatment decisions.
Key point: ctDNA testing may be used when tissue testing is challenging, infeasible, risky, delayed, or required by drug indication; negative/inconclusive results should prompt tissue confirmation.
Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point: Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"claudin 18.2"[tiab] OR CLDN18.2[tiab] OR zolbetuximab[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.